Novel triplex-engineered, BRCA1-mutated cell lines for research
Novel triplex-engineered, BRCA1-mutated cell lines for research
批准号:
8239269
负责人:
PETER M GLAZER
金额:
$20.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-01-13 至 2013-12-31
关键词:
AddressAlkylating AgentsAllelesBRCA1 MutationBRCA1 ProteinBRCA1 geneBiological AssayBiologyBreastCancer BiologyCell CycleCell LineCell physiologyCellsCharacteristicsCodeCommunitiesDNADNA DamageDNA RepairDevelopmentDouble Strand Break RepairEngineeringEpithelial CellsFoundationsFunding MechanismsGenesGenotypeGrowthHereditary Malignant NeoplasmHumanHuman Cell LineInheritedKaryotypeKnock-outMalignant neoplasm of ovaryMammary glandMediatingMessenger RNAMethodologyModelingModificationMutateMutationNon-MalignantPhasePoint MutationPredispositionResearchResourcesSFN geneSister Chromatid ExchangeTechniquesTechnologyTelomeraseTestingTimeTranscriptional RegulationWomanWorkbasecarcinogenesiscrosslinkdesignmalignant breast neoplasmmutantnovelresponsetriple helix
中文摘要
描述(由申请人提供):具有BRCA1基因遗传突变的女性患乳腺癌和卵巢癌的易感性显著增加。然而,由于缺乏合适的人类细胞系模型,特异性BRCA1突变以及BRCA1位点杂合性对乳腺上皮细胞生物学和乳腺癌发生的影响的重点研究受到了阻碍。为了解决这一缺陷,我们建议使用基于三螺旋的基因编辑技术在BRCA1位点引入精确定义的基因型,来设计新的人类乳腺来源的非恶性细胞系。这些基因型包括BRCA1基因的野生型、杂合型或纯合型突变,这些突变涉及人类家族性癌症中发现的两种常见有害等位基因(185delAG和532insc)。这些独特匹配的BRCA1野生型、杂合子和纯合子突变细胞系将使具有BRCA1基因型的乳腺源性细胞之间的生理相关比较成为可能。我们将描述这些细胞BRCA1功能的关键方面,包括转录调控、DNA损伤反应和DNA修复。
英文摘要
DESCRIPTION (provided by applicant): Women with one inherited mutation in the BRCA1 gene have a substantially increased predisposition to breast and ovarian cancer. However, focused study of the impact of specific BRCA1 mutations and, importantly, of heterozygosity at the BRCA1 locus, on the biology of breast epithelial cells and on breast carcinogenesis has been hampered by the lack of suitable human cell line models. To address this shortcoming, we propose to engineer novel human breast-derived, non-malignant cell lines using triplex-helix-based gene editing technology to introduce precisely defined genotypes at the BRCA1 locus. These genotypes will consist of wild-type, heterozygous, or homozygous mutations at the BRCA1 gene for two of the common deleterious alleles found in human familial cancers (185delAG and 5382insC). These unique matched sets of BRCA1 wild-type, heterozygous, and homozygous mutant cell lines will enable physiologically relevant comparisons between otherwise isogenic, breast-derived cells with defined genotypes for BRCA1. We will characterize these cells for key aspects of BRCA1 function, including regulation of transcription and of DNA damage responses and DNA repair.
PUBLIC HEALTH RELEVANCE: Inherited mutations in the BRCA1 gene are a major factor in breast carcinogenesis, but focused study of the impact of specific BRCA1 mutations has been hampered by the lack of suitable human cell lines. To address this shortcoming, we propose to engineer novel human breast-derived, non-malignant cell lines using a novel gene editing technology to introduce precisely defined mutations in the BRCA1 gene in human breast- derived cells. These unique matched sets of cells will enable important and physiologically relevant comparisons among breast-derived cells with defined genotypes for BRCA1, and they will be made readily available to the scientific community to facilitate a wide range of carcinogenesis and cancer biology studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PNA Nanoparticles for Gene Editing In Vivo
-
批准号:10198735
-
项目类别:
-
资助金额:$40.42万
-
财政年份:2019
-
负责人:PETER M GLAZER
-
依托单位:
PNA Nanoparticles for Gene Editing In Vivo
-
批准号:9804726
-
项目类别:
-
资助金额:$42.11万
-
财政年份:2019
-
负责人:PETER M GLAZER
-
依托单位:
PNA Nanoparticles for Gene Editing In Vivo
-
批准号:10414795
-
项目类别:
-
资助金额:$40.42万
-
财政年份:2019
-
负责人:PETER M GLAZER
-
依托单位:
Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung
-
批准号:10274829
-
项目类别:
-
资助金额:$75.68万
-
财政年份:2018
-
负责人:PETER M GLAZER
-
依托单位:
Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung
-
批准号:10706300
-
项目类别:
-
资助金额:$114.48万
-
财政年份:2018
-
负责人:PETER M GLAZER
-
依托单位:
Poly(amine-co-ester)s for targeted delivery of gene editing agents to treat cystic fibrosis in animal models: SCGE Disease Models Studies Supplement
-
批准号:10619840
-
项目类别:
-
资助金额:$49.82万
-
财政年份:2018
-
负责人:PETER M GLAZER
-
依托单位:
Novel DNA Repair Inhibitors for Cancer Therapy
-
批准号:9388067
-
项目类别:
-
资助金额:$77.33万
-
财政年份:2017
-
负责人:PETER M GLAZER
-
依托单位:
Novel DNA Repair Inhibitors for Cancer Therapy
-
批准号:10204894
-
项目类别:
-
资助金额:$100.49万
-
财政年份:2017
-
负责人:PETER M GLAZER
-
依托单位:
Novel DNA Repair Inhibitors for Cancer Therapy
-
批准号:10456727
-
项目类别:
-
资助金额:$98.49万
-
财政年份:2017
-
负责人:PETER M GLAZER
-
依托单位:
Novel DNA Repair Inhibitors for Cancer Therapy
-
批准号:9981673
-
项目类别:
-
资助金额:$100.49万
-
财政年份:2017
-
负责人:PETER M GLAZER
-
依托单位:
Yale Cancer Biology Training Grant
-
批准号:10170726
-
项目类别:
-
资助金额:$44.14万
-
财政年份:2016
-
负责人:PETER M GLAZER
-
依托单位:
Yale Cancer Biology Training Grant
-
批准号:10394345
-
项目类别:
-
资助金额:$40.59万
-
财政年份:2016
-
负责人:PETER M GLAZER
-
依托单位:
Yale Cancer Biology Training Grant
-
批准号:10599891
-
项目类别:
-
资助金额:$45.59万
-
财政年份:2016
-
负责人:PETER M GLAZER
-
依托单位:
Bifunctional Antibodies for Melanoma Therapy
-
批准号:8755327
-
项目类别:
-
资助金额:$45.94万
-
财政年份:2014
-
负责人:PETER M GLAZER
-
依托单位:
In vivo genomic editing of hematopoietic cells for HIV resistance
-
批准号:9110812
-
项目类别:
-
资助金额:$60.79万
-
财政年份:2014
-
负责人:PETER M GLAZER
-
依托单位:
Bifunctional Antibodies for Melanoma Therapy
-
批准号:8916650
-
项目类别:
-
资助金额:$44.27万
-
财政年份:2014
-
负责人:PETER M GLAZER
-
依托单位:
Yale Cancer Center NCTN
-
批准号:8605651
-
项目类别:
-
资助金额:$55.15万
-
财政年份:2014
-
负责人:PETER M GLAZER
-
依托单位:
Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer Therapy
-
批准号:8500076
-
项目类别:
-
资助金额:$34.52万
-
财政年份:2013
-
负责人:PETER M GLAZER
-
依托单位:
Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer Therapy
-
批准号:8826075
-
项目类别:
-
资助金额:$34.55万
-
财政年份:2013
-
负责人:PETER M GLAZER
-
依托单位:
Novel triplex-engineered, BRCA1-mutated cell lines for research
-
批准号:8412753
-
项目类别:
-
资助金额:$24.43万
-
财政年份:2012
-
负责人:PETER M GLAZER
-
依托单位:
海外基金